Us Bancorp \De\ Viridian Therapeutics, Inc.\De Transaction History

Us Bancorp \De\

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 03, 2023	SELL	$15.16 - $24.7 $289,070 - $470,979	-19,068 Reduced 99.81%	37 $0
Q2 2023 Aug 09, 2023	SELL	$22.57 - $29.67 $31,372 - $41,241	-1,390 Reduced 6.78%	19,105 $454,000
Q1 2023 May 09, 2023	BUY	$25.04 - $37.6 $232,195 - $348,664	9,273 Added 82.63%	20,495 $521,000
Q4 2022 Feb 13, 2023	BUY	$18.78 - $29.74 $210,749 - $333,742	11,222 New	11,222 $327,000

179

76.8M

581K

439K

Ticker VRDN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,888,900
Market Cap $839M
Description
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

Stay updated on Us Bancorp \De\ with notifications on news.